Alcohol and Drug Foundation (Australia), April 27th 2020 There are now new challenges for people who access opioid replacement therapy (ORT) due to the COVID-19 (coronavirus) pandemic. Many may be experiencing anxiety and fear due to COVID-19 and trying to reduce and mitigate these feelings is vital. In most cases, people who are on ORT are required to visit their health clinic or pharmacy on a...
Transgender women taking PrEP have lower levels of PrEP drugs than cisgender men
aidsmap/nam, November 9th 2018 A study presented at October’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in their blood that are about 25% lower than those in cisgender men, and levels in rectal tissue cells...
The updated 2017 ASHM HIV pre-exposure prophylaxis (PrEP) Guidelines
Journal of Virus Eradication, 2017; 3: 168–184 Daily use of co-formulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine‘s...
Evidence that “on-demand” PrEP taken before and after sex can prevent HIV
BETA Blog, September 8, 2016 How many doses of Truvada-based PrEP (pre-exposure prophylaxis) are needed to provide adequate protection against HIV? Might it be possible to take PrEP only before and after sex—instead of every day? A recent article published in The Lancet HIV provides insight into this very question. Read more here Access Lancet HIV abstract here (for full text please see your...
New PrEP studies will be a challenge, statisticians warn
nam/aidsmap, Published: 26 January 2016 Two statisticians involved in the PROUD and iPrEx trials of pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design. David Dunn of the UK Medical Research Council and David Glidden of the University of California, San Francisco say that statisticians will need to choose and analyse...
Efficacy of major chlamydia drug confirmed
ScienceDaily, December 23, 2015 In one of the most tightly controlled trials ever conducted of drugs used to treat sexually transmitted infections, researchers at the University of Alabama at Birmingham have confirmed that azithromycin remains effective in the treatment of urogenital chlamydia. In a study published Dec. 24 in the New England Journal of Medicine, the research team compared two of...